Floodgates Open For Tecfidera Rivals
Cipla, Dr Reddy’s And Camber Confirm Launches In US
Following Mylan’s initial launch of a generic rival to Biogen’s $3.8bn Tecfidera brand, other generics companies are now following the firm into the US dimethyl fumarate market.
You may also be interested in...
Biogen Sells Samsung Bioepis Stake In $2.3bn Buyout
Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.
Sandoz Canada Debuts Tecfidera Rival
Sandoz has announced its launch of a generic rival to Tecfidera in Canada, with the firm among the first generics to be issued a notice of compliance by Health Canada.
MSN Deals Out Of Movantik But Two ANDA Filers Remain
India’s MSN Laboratories is set to move on a generic version of RedHill Biopharma’s Movantik (naloxegol oxalate) for opioid-induced constipation ahead of patent expiry under the terms of a patent-litigation settlement agreement.